Back to News
Market Impact: 0.3
Ascendis Announces Planned $400 Million Share Repurchase Program
Source: GlobeNewswire
Capital Returns (Dividends / Buybacks)Healthcare & Biotech
Ascendis Pharma's board authorized a share-repurchase program of up to $400 million. The buyback signals management confidence and provides a potential support to ASND shares, though the announcement provided no timing, purchase pace, or funding details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
ASND0.55
More News
- Our next steps for Alphabet stock after earnings disappoint at nearly every turn
- Microsoft’s strong quarter backs up its stock rebound. Here's our new price target
- Aker BP Q3 profit tops forecast on $870 million writedown reversal
- FedEx's soft holiday-quarter outlook doesn't change our view on the stock
- Microsoft’s cloud growth accelerates, and so too does the spending
- SK Hynix says the memory-chip shortage will last until 2030—and more than half its production is booked for the next two years